Longeveron (LGVN) announced the appointment of Nataliya Agafonova, M. D., as the Company’s Chief Medical Officer, CMO, effective as of July 1, 2023. As CMO, Dr. Agafonova will lead Longeveron’s global clinical development and regulatory strategy for the Company’s investigational products. Dr. Agafonova joins Longeveron from Otsuka Pharmaceutical (OTSKY), where she served as Clinical Development Lead, Senior Medical Director, and Product Development Chair.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LGVN:
- Longeveron Files Registration Statement for Rights Offering
- Longeveron files registration statement for rights offering
- Longeveron appoints Wa’el Hashad, Khoso Baluch, Jeffrey Pfeffer to board
- Longeveron Welcomes Three New Prominent Board Members
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue